SCHEMBL2676369

SCHEMBL2676369

O=C(O)c1c(CN2C3CC[C@@H]2CC(O)C3)n(-c2ccccc2)c(=O)c2ccccc12

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HTR3E A5X5Y0 3/20 0.40
HTR3B O95264 3/20 0.40
HTR3A P46098 3/20 0.40
HTR3D Q70Z44 3/20 0.40
HTR3C Q8WXA8 3/20 0.40
NPSR1 Q6W5P4 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
MAPK1 P28482 1/20 0.40
LTA4H P09960 3/20 0.35
KMT2A Q03164 1/20 0.34
RECQL P46063 1/20 0.34
KDM4E B2RXH2 1/20 0.34
PGR P06401 1/20 0.34
LMNA P02545 1/20 0.34
ALDH1A1 P00352 1/20 0.34
HSD17B10 Q99714 1/20 0.34
USP14 P54578 1/20 0.34
KCNH2 Q12809 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1719365 1.00 HTR3E (0.40) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL2676363 1.00 HTR3E (0.40) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL2676365 1.00 HTR3E (0.40) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL1719367 1.00 HTR3E (0.40) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL1717437 0.83 TACR3 (0.43) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL2677338 0.82 USP14 (0.41) NPSR1L3MBTL1MAPK1KMT2AUSP14
SCHEMBL2675572 0.81 NPSR1 (0.40) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL2675209 0.81 ALDH1A1 (0.40) NPSR1L3MBTL1MAPK1KMT2AKDM4E
SCHEMBL2675206 0.81 ALDH1A1 (0.40) NPSR1L3MBTL1MAPK1KMT2AKDM4E
SCHEMBL2676863 0.81 ALDH1A1 (0.40) NPSR1L3MBTL1MAPK1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173639-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-05-08 US claimed
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2009-06-04 US claimed
US-8173639-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-05-08 US disclosed
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS KCNQ3, KCNK3, GRIK3 HTR3E 275/4885HTR3B 123/4885HTR3A 90/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.